GlassScriptPhysician profile
Daniel Rene Sanchez
NPI 1164482428
$2,232.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $369 · 2021: $310 · 2022: $308 · 2023: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $611.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $422.11 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Sunovion Pharmaceuticals INC. | $249.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $232.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $218.08 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $177.36 | 2019-2023 | Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $94.65 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.25 | 2020-2022 | |
| Abbvie INC. | $42.38 | 2021-2023 | Vraylar |
| Bausch Health US, LLC | $35.77 | 2021-2023 | Wellbutrin |
| Alkermes, INC. | $30.57 | 2019-2021 | |
| Noven Therapeutics, LLC | $27.49 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.51 | 2019 | |
| Indivior INC. | $14.42 | 2019 | |
| Shire North American Group INC | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.